Skip to main content
Top
Published in:

Open Access 01-06-2025 | Prediabetes | Research article

Prevalence and incidence of prediabetes in Latin America. A systematic review and meta-analysis

Authors: Víctor Juan Vera-Ponce, Joan A. Loayza-Castro, Fiorella E. Zuzunaga-Montoya, Nataly Mayely Sanchez-Tamay, Juan Carlos Bustamante-Rodríguez, Lupita Ana Maria Valladolid-Sandoval, Luisa Erika Milagros Vásquez-Romero, Carmen Inés Gutiérrez de Carrillo

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2025

Login to get access

Abstract

Introduction

Prediabetes represents a significant public health challenge in Latin America. Its prevalence varies considerably depending on the diagnostic criteria used, which hinders a precise understanding of its magnitude in the region.

Objective

To estimate the prevalence and incidence of prediabetes in Latin America through a systematic review (SR).

Methods

A SR and meta-analysis was conducted searching through October 25, 2024 in SCOPUS, EMBASE, Web of Science, and PubMed. Studies were included if they: (1) used probabilistic sampling methods, (2) included adult participants (≥ 18 years), (3) assessed prediabetes using WHO criteria, fasting glucose, postprandial glucose, or HbA1c, and (4) were published in English, Spanish, or Portuguese. Studies using non-probabilistic sampling, focusing on specific medical conditions, or lacking sufficient data to calculate prevalence or incidence were excluded. Random-effect models were used to estimate pooled prevalence, with heterogeneity assessed using I² statistics and publication bias through funnel plots.

Results

Twenty-five studies from 9 countries published between 1992 and 2023 were analyzed. The pooled prevalence of prediabetes was 24% (95% CI: 18–30%). According to specific criteria, the prevalences were: WHO 11% (95% CI: 5–18%), FG 18% (95% CI: 10–27%), PPG 20% (95% CI: 3–46%), and HbA1c 32% (95% CI: 21–52%). High heterogeneity was observed among studies (I² = 99–100%, p < 0.001). Only one study analyzed the incidence, which was 12.8%.

Conclusions

Prediabetes prevalence in Latin America is high, with significant variations by diagnostic criteria. The limited number of incidence studies and high heterogeneity highlight the need for standardized approaches in future research. Implementation of preventive strategies and strengthening of epidemiological surveillance systems are crucial for addressing this public health challenge.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Prevalence and incidence of prediabetes in Latin America. A systematic review and meta-analysis
Authors
Víctor Juan Vera-Ponce
Joan A. Loayza-Castro
Fiorella E. Zuzunaga-Montoya
Nataly Mayely Sanchez-Tamay
Juan Carlos Bustamante-Rodríguez
Lupita Ana Maria Valladolid-Sandoval
Luisa Erika Milagros Vásquez-Romero
Carmen Inés Gutiérrez de Carrillo
Publication date
01-06-2025
Publisher
Springer International Publishing
Keyword
Prediabetes
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2025
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-024-01549-6

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Log in / Register to watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more